PROFESSIONAL EDITION

The largest community of pharma leaders

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

LAWRENCEVILLE, N.J.–(BUSINESS WIRE)–Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles